Two children presented with autoimmune alternating hypo- and hyperthyroidism related to the presence of blocking and stimulating thyroid antibodies. It was difficult to control their thyroid function adequately with an appropriate single drug regimen, and both children underwent total thyroidectomy with subsequent stable management with levothyroxine replacement therapy postsurgically. Although this phenomenon is well described in adults, this report is the first of such occurrence in children. The possible mechanism for the variation in the type of clinical presentation and options for management are discussed.
MiyauchiAAminoNTamakiHKumaK. Coexistence of thyroid-stimulating and thyroid blocking antibodies in a patient with Graves disease who had transient hypothyroidism. Am J Med. 1988;85:418-420.
2.
KasagiKTakedaKGoshiK. Presence of both stimulating and blocking types of TSH-receptor antibodies in sera from three patients with primary hypothyroidism. Clin Endocrinol (Oxf). 1990;32:253-260.
3.
TakedaKTakamatsuJKasagiK. Development of hyperthyroidism following primary hypothyroidism: a case report with changes in thyroid-related antibodies. Clin Endocrinol (Oxf). 1988;28:341-344.
4.
KimWBChungHKParkYJ. The prevalence and clinical significance of blocking thyrotropin receptor antibodies in untreated hyperthyroid Graves disease. Thyroid. 2000;10:579-586.
5.
BeckK. Thyroid antibodies in endocrine ophthalmopahty. A review. Acta Endocrinol (Copenh). 1989;121:117-122.
6.
KohnLDSuzukiKHoffmanWH. Characterization of monoclonal thyroid-stimulating and thyrotropin binding-inhibiting autoantibodies from a Hashimoto’s patient whose children had intrauterine and neonatal thyroid disease. J Clin Endocrinol Metab. 1997;82:3998-4009.
7.
YavinEYavinZSchneiderMDKohnLD. Monoclonal antibodies to the thyrotropin receptor: implications for receptor strucuture and the action of autoantibodies in Graves disease. Proc Natl Acad Sci U S A. 1981;78:6680-6684.
8.
EaleyPAKohnLDEkinsRPMarshallNJ. Characterization of monoclonal antibodies derived from lymphocytes from Graves disease patients in a cytochemical bioassay for thyroid stimulators. J Clin Endocrinol Metab. 1984;58:909-914.
9.
KohnLDAlvarezFMarcocciC. Monoclonal antibody studies defining the origin and properties of autoantibodies in Graves disease. Ann N Y Acad Sci. 1986;475:157-173.
10.
TaharaKBanTMinegishiTKohnLD. Immunoglobulins from Graves disease patients interact with different sites on TSH receptor/LH-CG receptor chimera than either TSH or immunoglobulins from idiopathic myxedema patients. Biochem Biophys Res Commun. 1991;179:70-77.
11.
KimWBChoBYParkHY. Epitopes for thyroid stimulating antibodies in Graves’ sera: a possible link of heterogeneity to differences in response to antithyroid drug treatment. J Clin Endocrinol Metab. 1996;81:1758-1767.
12.
KosugiSBanTKohnLD. Identification of thyroid stimulating antibody-specific interaction sites in the N-terminal region of the thyrotropin receptor. Mol Endocrinol. 1993;7: 114-130.
13.
WatanabeYTaharaKHiraiATadaHKohnLDAminoN. Subtypes of anti-TSH receptor antibodies classified by bio- and conversion assays using CHO cells expressing wild type or chimeric human TSH receptor. Thyroid. 1997;7:13-19.
14.
ValenteWAVittiPRotellaCM. Antibodies that promote thyroid growth: a distinct population of thyroid-stimulating autoantibodies. N Engl J Med. 1983;309:1028-1034.
15.
KimWBChungHKLeeHKKohnLDTaharaKChoBY. Changes in epitopes for thyroid stimulating antibodies in Graves’ disease sera during treatment of hyperthyroidism: therapeutic implications. J Clin Endocrinol Metab. 1997;82:1953-1959.
16.
TallstedtLLundellGTørringO. Occurance of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326: 1733-1738.
17.
BartalenaLMarcocciCBogazziF. Relationship between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73-78.
18.
MittendorfEMcHenryC. Thyroidectomy for selected patients with thyrotoxicosis. Arch Otolaryngol Head Neck Surg. 2001;127:61-65.
